EA201290170A3 - Добавляемые в активное вещество однородные, жесткие, сферические нанопористые частицы фосфата кальция и способы их производства и использования - Google Patents

Добавляемые в активное вещество однородные, жесткие, сферические нанопористые частицы фосфата кальция и способы их производства и использования

Info

Publication number
EA201290170A3
EA201290170A3 EA201290170A EA201290170A EA201290170A3 EA 201290170 A3 EA201290170 A3 EA 201290170A3 EA 201290170 A EA201290170 A EA 201290170A EA 201290170 A EA201290170 A EA 201290170A EA 201290170 A3 EA201290170 A3 EA 201290170A3
Authority
EA
Eurasian Patent Office
Prior art keywords
particles
active substance
compositions
added
active matter
Prior art date
Application number
EA201290170A
Other languages
English (en)
Other versions
EA027992B1 (ru
EA201290170A2 (ru
Inventor
Тецуро Огава
Акира Ямамото
Original Assignee
Лаборэтори Скин Кэа, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лаборэтори Скин Кэа, Инк. filed Critical Лаборэтори Скин Кэа, Инк.
Publication of EA201290170A2 publication Critical patent/EA201290170A2/ru
Publication of EA201290170A3 publication Critical patent/EA201290170A3/ru
Publication of EA027992B1 publication Critical patent/EA027992B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241Containing particulates characterized by their shape and/or structure
    • A61K8/0279Porous; Hollow
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24Phosphorous; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/008Preparations for oily skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/56Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/773Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Рассматриваются однородные, жесткие сферические нанопористые частицы фосфата кальция, определяющие внутреннее пространство и количество активного вещества, присутствующего во внутреннем пространстве. Также рассматриваются композиции для топической доставки, включающие частицы, добавляемые в активное вещество, а также способы производства частиц и топических композиций. Частицы и композиции используются в ряде различных применений, включая доставку активного вещества.
EA201290170A 2008-09-23 2009-09-23 Способ получения однородных, жестких, сферических, нанопористых частиц фосфата кальция, содержащих активное вещество EA027992B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9950008P 2008-09-23 2008-09-23
PCT/US2009/058108 WO2010039560A2 (en) 2008-09-23 2009-09-23 Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same

Publications (3)

Publication Number Publication Date
EA201290170A2 EA201290170A2 (ru) 2012-11-30
EA201290170A3 true EA201290170A3 (ru) 2013-03-29
EA027992B1 EA027992B1 (ru) 2017-09-29

Family

ID=42074119

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290170A EA027992B1 (ru) 2008-09-23 2009-09-23 Способ получения однородных, жестких, сферических, нанопористых частиц фосфата кальция, содержащих активное вещество

Country Status (17)

Country Link
US (5) US8535723B2 (ru)
EP (1) EP2480210A4 (ru)
JP (1) JP5730316B2 (ru)
KR (4) KR101689635B1 (ru)
CN (1) CN102802610A (ru)
AU (1) AU2009298814B2 (ru)
BR (1) BR112012006635B8 (ru)
CA (1) CA2778604C (ru)
CL (1) CL2012000726A1 (ru)
EA (1) EA027992B1 (ru)
IL (2) IL218808A (ru)
MX (1) MX356209B (ru)
MY (1) MY162982A (ru)
NZ (1) NZ599544A (ru)
SG (2) SG10201406431QA (ru)
WO (1) WO2010039560A2 (ru)
ZA (1) ZA201202948B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101689635B1 (ko) * 2008-09-23 2016-12-26 라보라토리 스킨 케어, 인크. 활성제 장입된 균일하고 강성이면서 구형의 나노다공성 인산칼슘 입자 및 그의 제조 방법과 그의 용도
WO2010107964A1 (en) * 2009-03-18 2010-09-23 Pleiades Cardio-Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US8445002B2 (en) * 2009-05-06 2013-05-21 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US20120207836A1 (en) * 2009-08-19 2012-08-16 Bayer Pharma Aktiengesellschaft Drug delivery systems (wafer) for pediatric use
EP2533753B1 (en) * 2009-11-10 2022-07-06 Laboratory Skin Care, Inc. Sunscreen compositions comprising uniform, rigid, spherical, nanoporous calcium phosphate particles, and methods of making and using the same
CN103781485A (zh) * 2011-01-19 2014-05-07 护肤品实验室有限公司 局部米诺环素组合物及其使用方法
CN104039312A (zh) * 2011-08-16 2014-09-10 实验室护肤股份有限公司 细干颗粒腺苷组合物和包括其的局部制剂
CN102552913B (zh) * 2012-01-19 2013-06-19 中国科学院上海硅酸盐研究所 一种纳米结构磷酸钙双载药体系及其制备方法
CN103284929B (zh) * 2012-02-23 2015-08-12 黄曦 一种护肤品及其制备方法
US11844852B2 (en) * 2012-02-23 2023-12-19 Fe:I Beauty Tech, Inc. Skincare product and method of preparation thereof
CN102579355B (zh) * 2012-03-19 2013-03-06 天津大学 米托蒽醌纳米磷酸氢钙制剂及其制备方法
CZ2012724A3 (cs) * 2012-10-24 2014-07-23 Agra Group, A.S. Mezoporézní částice, jejich použití a přípravek je obsahující
NZ713342A (en) * 2013-03-15 2020-12-18 Laboratory Skin Care Inc Fine dry particulate retinoid active agent compositions and topical formulations including the same
MX354474B (es) * 2013-03-15 2018-03-07 Laboratory Skin Care Inc Composiciones de agente activo resveratrol particuladas, secas y finas y formulaciones topicas que incluyen las mismas.
CN104856889B (zh) * 2014-09-22 2017-05-10 北京大学口腔医学院 缓释氯己定无定形磷酸钙纳米颗粒的制备方法
CN105336873B (zh) * 2015-11-05 2018-12-07 广州竞择微电子技术有限公司 一种柔性光电子器件用基板及其制备方法
CA3012333A1 (en) 2016-02-01 2017-08-10 Incarda Therapeutics, Inc. Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
JP2019517590A (ja) 2016-06-03 2019-06-24 エム エ ペ ファルマ アクチェンゲゼルシャフト 多孔性賦形剤を含む経鼻用医薬組成物
EP3570848B1 (en) 2017-01-20 2023-06-07 M Et P Pharma AG Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants
KR20200003199A (ko) 2017-05-10 2020-01-08 인카다 테라퓨틱스, 인크. 폐 투여에 의해 심장 병태를 치료하기 위한 단위 용량, 에어로졸, 키트 및 방법
JP6961504B2 (ja) * 2018-01-26 2021-11-05 国立大学法人 岡山大学 徐放性デバイス
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
KR102221493B1 (ko) * 2018-12-12 2021-02-26 성균관대학교산학협력단 핵산 기반의 칼슘 포스페이트 나노 소재를 합성하는 방법 및 이에 의해 합성된 핵산 기반의 칼슘 포스페이트 나노 소재
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
CN113054121B (zh) * 2019-12-28 2022-07-05 Tcl科技集团股份有限公司 纳米材料及其制备方法、半导体器件

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218255A (en) * 1976-08-30 1980-08-19 University Of Dayton Porous ceramic carriers for controlled release of proteins, polypeptide hormones, and other substances within human and/or other mamillian species and method
US5055307A (en) * 1988-12-29 1991-10-08 Asahi Kagaku Kogyo Kabushiki Kaisha Slow release drug delivery granules and process for production thereof
JPH0832551B2 (ja) 1989-06-24 1996-03-29 旭光学工業株式会社 多孔質リン酸カルシウム系化合物粒子及びその製造方法
JPH07330319A (ja) * 1994-06-03 1995-12-19 Asahi Optical Co Ltd 皮膚清浄用粉末組成物
US5837728A (en) * 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US6579516B1 (en) * 1995-06-13 2003-06-17 Zahra Mansouri Methods of delivering materials into the skin, and compositions used therein
US6096324A (en) * 1995-06-13 2000-08-01 Laboratory Skin Care Methods of delivering materials into the skin, and compositions used therein
US6416774B1 (en) * 1996-05-09 2002-07-09 The Trustees Of The University Of Pennsyvania Hollow bone mineral-like calcium phosphate particles
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
AUPQ573300A0 (en) * 2000-02-21 2000-03-16 Australian Nuclear Science & Technology Organisation Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use
JP2004075662A (ja) * 2002-06-20 2004-03-11 Mukku:Kk 徐放性組成物、その製造方法およびその製剤
KR20060052695A (ko) 2003-06-18 2006-05-19 가부시키가이샤 엘티티 바이오파마 약물 함유 서방성 미립자, 이의 제조방법 및 이를 함유하는약제
FR2856594B1 (fr) * 2003-06-26 2006-03-03 Oreal Particules poreuses chargees en compose(s) actif(s) cosmetique(s) ou pharmaceutique(s)
US20050031559A1 (en) 2003-07-07 2005-02-10 L'oreal Cosmetic composition for caring for and/or making up skin
JP2007001865A (ja) * 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
DE602005021756D1 (de) 2004-02-13 2010-07-22 Nod Pharmaceuticals Inc Partikel mit kern aus calciumphosphat-nanopartikeln, biomolekül und gallensäure, herstellungsverfahren und therapeutische verwendung
EP1737378A2 (en) * 2004-04-02 2007-01-03 Baylor College of Medicine Novel modification of medical prostheses
US20060073205A1 (en) * 2004-10-04 2006-04-06 Kotoe Ohta Controlled release granules comprising porous silica core
US20060257492A1 (en) * 2005-05-13 2006-11-16 Depuy Products, Inc. Suspension of calcium phosphate particulates for local delivery of therapeutic agents
CN1813657A (zh) * 2005-12-15 2006-08-09 孙振淋 纳米磷酸钙类盐在化妆产品中的应用方法
CN100509695C (zh) * 2006-02-21 2009-07-08 西南交通大学 多孔羟基磷灰石和磷酸钙陶瓷的制备方法
FR2898807B1 (fr) * 2006-03-23 2008-12-05 Oreal Composition comprenant de l'hydroxyapatite et un sel de calcium pour renforcer la fonction barriere de la peau et/ou des semi-muqueuses
CN100460016C (zh) * 2006-04-21 2009-02-11 华南理工大学 介孔磷酸钙纳米颗粒及其制备方法和应用
KR101689635B1 (ko) * 2008-09-23 2016-12-26 라보라토리 스킨 케어, 인크. 활성제 장입된 균일하고 강성이면서 구형의 나노다공성 인산칼슘 입자 및 그의 제조 방법과 그의 용도
US8445002B2 (en) * 2009-05-06 2013-05-21 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
NZ713342A (en) * 2013-03-15 2020-12-18 Laboratory Skin Care Inc Fine dry particulate retinoid active agent compositions and topical formulations including the same

Also Published As

Publication number Publication date
KR20180089553A (ko) 2018-08-08
KR101689635B1 (ko) 2016-12-26
KR20170096241A (ko) 2017-08-23
US10028903B2 (en) 2018-07-24
CL2012000726A1 (es) 2013-01-11
CA2778604A1 (en) 2010-04-08
EA027992B1 (ru) 2017-09-29
US8535723B2 (en) 2013-09-17
US20140199400A1 (en) 2014-07-17
CN102802610A (zh) 2012-11-28
JP2013505293A (ja) 2013-02-14
IL255112A0 (en) 2017-12-31
IL218808A (en) 2017-10-31
US20240082147A1 (en) 2024-03-14
EP2480210A2 (en) 2012-08-01
AU2009298814B2 (en) 2016-05-05
SG10201406431QA (en) 2014-11-27
CA2778604C (en) 2021-10-05
US20190117558A1 (en) 2019-04-25
US20210015739A1 (en) 2021-01-21
EP2480210A4 (en) 2016-07-13
IL218808A0 (en) 2012-06-28
BR112012006635B8 (pt) 2021-05-25
BR112012006635B1 (pt) 2021-04-06
US20100086606A1 (en) 2010-04-08
KR20120104188A (ko) 2012-09-20
ZA201202948B (en) 2014-08-27
US10758478B2 (en) 2020-09-01
JP5730316B2 (ja) 2015-06-10
MY162982A (en) 2017-07-31
BR112012006635A2 (pt) 2016-05-03
WO2010039560A3 (en) 2015-05-21
MX356209B (es) 2018-05-18
WO2010039560A2 (en) 2010-04-08
EA201290170A2 (ru) 2012-11-30
KR20160083953A (ko) 2016-07-12
AU2009298814A1 (en) 2012-06-21
NZ599544A (en) 2014-04-30
IL255112B (en) 2019-09-26
SG10201903125QA (en) 2019-05-30
MX2012003542A (es) 2012-09-07

Similar Documents

Publication Publication Date Title
EA201290170A3 (ru) Добавляемые в активное вещество однородные, жесткие, сферические нанопористые частицы фосфата кальция и способы их производства и использования
CL2020000468A1 (es) Uso de una formulación estable que comprende una enzima de reemplazo para la enzima lisosomal (divisional solicitud 201801220)
EA201391030A1 (ru) Композиции моноциклина для местного применения и способы их применения
EA201200939A1 (ru) Липиды, липидные композиции и способы их применения
EA201791850A1 (ru) Борсодержащие малые молекулы
EA201171286A1 (ru) Новая технология изготовления индометацина
EA201291034A1 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ B-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
EA201390184A1 (ru) Активирующие амрк гетероциклические соединения и способы их использования
EA201171285A1 (ru) Новая технология изготовления диклофенака
EA201190295A1 (ru) Композиции для дермальной доставки, содержащие комплексы активного агента с частицами фосфата кальция, и способы их применения
TR200806298A2 (tr) Farmasötik formülasyon
MX2010004389A (es) Formulaciones de vancomicina liposomales.
EA201171284A1 (ru) Новая технология изготовления напроксена
EA201300337A1 (ru) Композиция, содержащая пирипиропеновый инсектицид и основание
EA201490599A1 (ru) Соединения триазолопиридина в качестве ингибиторов фосфодиэстеразы pde10a
BR112013011845B8 (pt) enxaguatório bucal compreendendo aminoácido básico e conservante e uso cosmético do enxaguatório bucal
EA200870515A1 (ru) Моноциклические гетероарильные соединения
EA201201170A1 (ru) Гетариламинонафтиридины
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
EA201001569A1 (ru) Инкапсуляция биологически активных агентов
EA201391555A1 (ru) Составы суспензионного типа для местного применения, содержащие циклический депсипептид
EA201390467A1 (ru) Композиции антител и способы применения
TR201009167A2 (tr) Sefalosporin içeren farmasötik granüller.
EA201100625A1 (ru) Кристаллические комплексы пендиметалина и метазахлора
TW201129386A (en) Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU